过度表达circZNF720通过调节miR-421/MAPK9抑制肝细胞癌的进展
Feifei Yang1, Zhenjuan Zhuang1, Chunying Liu2
1Department of Pathology, Anqiu People's Hospital, No. 159 Xuefu street, Anqiu, Weifang, 262100, Shandong, China.
Molecular biotechnology
|December 30, 2023
概括
循环RNA ZNF720 (circZNF720) 通过向miR-421和MAPK9.9来抑制肝细胞癌 (HCC) 的进展. 低circZNF720表达与HCC预后不佳相关,这表明circZNF720是潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 肝细胞癌 (HCC) 的发病率和死亡率很高,预后不佳.
- 异常的循环RNA (circRNA) 表达与HCC恶性病有关.
- circZNF720在HCC进展中的特定作用尚不清楚.
研究的目的:
- 为了研究circZNF720对肝细胞癌 (HCC) 进展的影响.
- 阐明涉及circZNF720,miR-421和MAPK9.9的潜在调节机制.
- 评估circZNF720在HCC患者的预后价值.
主要方法:
- 细胞增殖,迁移,入侵和细胞亡分析 (CCK-8,Transwell,流细胞计).
- 卡普兰-梅尔生存分析用于预后评估.
- 分子机制研究包括qRT-PCR,双露西法酶记者测定和RIP分析.
主要成果:
- 发现 circZNF720 在HCC组织中表达低,与患者预后不佳相关.
- 过度表达circZNF720抑制了HCC细胞的增殖,迁移和入侵,同时增强了亡.
- circZNF720作为miR-421的miRNA海绵,miR-421针对MAPK9,揭示了一个circZNF720/miR-421/MAPK9调节轴.
结论:
- circZNF720通过抑制miR-421/MAPK9通路来抑制HCC的进展.
- circZNF720代表了肝细胞癌的潜在新型治疗点.
- 低circZNF720表达是HCC患者预后不佳的指标.
相关概念视频
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


